Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 5.37IPCO.TO -0.2DC.A.TO 0.28NESN-SIX 0MCK 27.62GOOG -1.47XLV 0.985TEVA 0.82
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.45
+0.48 (1.70%)
as of Aug 25, 2026, 5:51:24 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
SELL

Pfizer Inc(PFE)

Nov 23, 2020
He sold it about two weeks ago when they put out the vaccine news. He was looking to trim or sell anyway. They are going through the spin-off of their generic business (UpJohn). He does not think the vaccine will be a long term driver on their financials. They had a miss in their oncology program back in June that impacted the long term growth rate going forward.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$36.52

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 19, 2020
The positive vaccine news helped the stock rally but it has since given up the gains. There is not as much growth as you would like, and pay 13x earnings. Likes other names that has better growth. It has been moving sideways. The only reason to own it is for the dividend.
Photo of Stan WongStan Wong
No
Unlock Rating
$36.11

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2020
Allan Tong’s Discover Picks The divvy pays nearly 4%. Investors are already pushing up the Pfizer stock near 52-week highs and price target, both $41, though it trades at a PE of only 14.9x. Currently, one analyst rates Pfizer stock a strong buy, 11 more a buy, nine a hold, and one a sell, its strongest recommendations so far this year. It's a strong company, but upside may be limited. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
Photo of Stockchase DiscoverStockchase Discover
Owned
Unlock Rating
$37.43

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Oct 20, 2020
Tough to analyze now. He's awaiting their drug test results. They're in the middle of spinning off long-life assets, including Viagra (later this year or next). This spinning-off will transform Pfizer from boring long-life assets to focus on R&D drugs. He expects their Covid vaccine to succeed the first. The CEO issued an update Friday and the testing data so far looks promising. There haven't been any adverse test results yet. He expects data in 2-5 weeks. He's closely watching this. Their Covid vaccine will be a catalyst short-term.
Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$37.58

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 14, 2020
Likes healthcare because of demographics, but not her preference. In the process of building up their pipeline. Revenue portfolio will have another period of patent expiration. Wants to see more visibility on the pipeline, or perhaps an acquisition.
Photo of Christine PooleChristine Poole
No
Unlock Rating
$36.86

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Pfizer Inc(PFE)

Sep 24, 2020
Stochchase Research Editor: Michael O'Reilly PFE is a defensive Top Pick that pays a strong yield, with history of dividend growth and a strong balance sheet. It is one of the world's leading pharmaceutical companies with a robust pipeline of new products in development (targeting 25 new drugs to market by 2025). They are partnering to develop a COVID-19 vaccine that is now in stage 2/3 testing and has a contract with the US government for $1.95 billion for the first 100 million doses if successful. The company holds $1.8 billion in cash reserves. The yield is strong and is supported with a 58% payout ratio. We would buy this using a $31 stop-loss, looking for a return towards $42. Yield 4.22% (Analysts’ price target is $41.79)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$35.68

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 15, 2020
Pfizer is having an analysts day this week. She owns another large pharma (see today's top picks). All the pharmas have said they won't make a lot of money on the vaccine in the first phase at least. They're still building a pipeline of drugs, so she doesn't own it.
Photo of Christine PooleChristine Poole
No
Unlock Rating
$37.05

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 14, 2020
It's a bond with drugs. It doesn't have the pipeline of drugs to attract investors.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$37.01

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 04, 2020
One of the largest pharma companies in the world. They have done a good job rebuilding their pipeline of drugs. It's now better built with constant new products. They took a hit due to a cancer drug that didn't prove itself. You get a nice dividend. In the medical space, there are other names like Boston Scientific that could be a good alternative.
Photo of Jamie Murray Jamie Murray
Owned
Unlock Rating
$36.36

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 27, 2020

PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

Photo of Gordon ReidGordon ReidUnlock Rating
$37.81

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 24, 2020
(A Top Pick Sep 16/19, Down 9%) He bought it for stability and the dividend. They have new drugs, including a COVID one. Pays a solid 3.8% dividend. Not worried about this.
Photo of Bruce MurrayBruce Murray
Owned
Unlock Rating
$38.65

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 21, 2020
Trades at 14x PE and pays almost a 4% dividend. Tailwind is them working on a COVID-19 vaccine, like all its peers. They have a strong backlog of drugs that will come to market. No headwinds politically which is good.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$36.80

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 16, 2020

Went over the patent cliff and is in the process of redeveloping its pipeline. Attractive yield. Owns JNJ instead, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.

Photo of Christine PooleChristine Poole
No
Unlock Rating
$35.40

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 09, 2020

Main attractions are its cash flow and dividend. Being held back by low earnings growth, low single digits. Instead, look at Abbvie, Merck, or other names with growth but similar valuations.

Photo of Stan WongStan Wong
No
Unlock Rating
$33.50

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jun 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

Photo of Darren SissonsDarren SissonsUnlock Rating
$33.24

Stock price when the opinion was issued

$28.35

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 196 to 210 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.69$101.18
TFPM 0$
OGC.TO 0.03$43.25
SLB -0.545$53.455
ARG.TO 0.53$8.75

Today's Top Picks

SII.TO 5.37$192.56
IPCO.TO -0.2$35.02
DC.A.TO 0.28$5.43
NESN-SIX 0$
MCK 27.62$901.41

Popular Articles

Latest Sell Signals

RKLB -1.16$67.12
INTC 0.36$87.62
MSFT 3.13$490.44
WSP.TO -3.61$188.67
CLS.TO 12.54$419.9

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like